Morbidity and mortality associated with influenza virus infection have cut a wide swathe through medical history. Even with the development of killed virus vaccines, illness due to influenza virus infection continues to be a major health problem throughout the world. This may change over the next few years with the development of a new class of antiviral agents targeting the catalytic site of the viral neuraminidase enzyme. These agents have been demonstrated to be both efficacious and clinically beneficial. In addition, investigation into alternative anti-influenza targets continues. These include inhibitors of hemagglutinin-mediated functions, the viral polymerase and new inhibitors of M2 ion channel activity.